Selected stock price target news of the day - April 28th, 2025

By: Matthew Otto

Avantor Misses Q1 Revenue Target, Expands Cost Cuts

Avantor reported financial results for the first quarter ended March 31, 2025. Net sales were $1.58 billion, representing a 6% decrease compared to the prior-year period, with a 2% decline on an organic basis after accounting for a 1% negative impact from foreign currency translation. Revenue came in slightly below the consensus estimate of $1.61 billion.

Net income rose to $64.5 million from $60.4 million in the first quarter of 2024, while adjusted net income totaled $155.2 million. Adjusted EBITDA was $269.5 million, with an Adjusted EBITDA margin of 17%. Diluted GAAP earnings per share (EPS) was $0.09, and adjusted EPS was $0.23, matching the analyst consensus estimate. Operating cash flow for the quarter was $109.3 million, and free cash flow totaled $82.1 million. Avantor’s adjusted net leverage ratio stood at 3.2x as of quarter-end.

Segment results showed Laboratory Solutions net sales of $1.07 billion, a reported decrease of 8% year-over-year and a 3% decline on an organic basis, with adjusted operating income of $139 million and an adjusted operating margin of 13.1%. Bioscience Production reported net sales of $516.4 million, down 1% year-over-year and flat on an organic basis, with adjusted operating income of $123.4 million and a margin of 23.9%.

Analysts Lower Ratings and Price Targets Following Q1 Results

Barclays analyst Luke Sergott maintained an Overweight rating but lowered the price target from $18 to $15.
Morgan Stanley analyst Tejas Savant downgraded from Overweight to Equal-Weight and the price target from $25 to $15.
Baird analyst Catherine Schulte maintained an Outperform rating while reducing the price target from $21 to $17.
RBC Capital analyst Conor McNamara lowered the price target to $20.
TD Cowen analyst Dan Brennan downgraded from Buy to Hold and a price target at $15.5.

Which Analyst has the best track record to show on AVTR?

Analyst Tejas Savant (MORGAN STANLEY) currently has the highest performing score on AVTR with 3/8 (37.5%) price target fulfillment ratio. His price targets carry an average of $5.99 (31.51%) potential upside. Avantor stock price reaches these price targets on average within 89 days.

Eastman Chemical Beats Q1 EPS but Misses on Revenue

Eastman Chemical Company announced first-quarter 2025 financial results, reporting adjusted earnings per diluted share of $1.91, exceeding the analyst consensus estimate of $1.9 by $0.01. Sales revenue was $2.29 billion, below the consensus estimate of $2.35 billion and a 1% decrease from $2.31 billion in the first quarter of 2024.

Adjusted EBIT increased to $311 million from $274 million year over year. Reported EBIT rose to $302 million compared to $263 million in the prior-year period. Adjusted EBIT margin improved by 170 basis points. Segment-level performance showed a 4% sales revenue increase in Additives & Functional Products and a 4% increase in Chemical Intermediates, while Advanced Materials declined 4% and Fibers decreased 13%.

Sales volume/mix declined by 1%, with a 1% rise in selling prices partially offsetting the impact. Net earnings per diluted share increased from $1.39 in Q1 2024 to $1.57 in Q1 2025.

Cash used in operating activities totaled $167 million compared to $16 million in the first quarter of the prior year. Eastman returned $96 million to stockholders through dividend payments during the quarter.

Sales revenue in Advanced Materials declined due to 2% lower selling prices, 1% lower volume/mix, and unfavorable foreign currency impacts. In Additives & Functional Products, selling prices rose 3% and volume/mix increased 2%, partially offset by currency effects. In Fibers, a 12% volume/mix decline and 1% lower selling prices reduced revenue.

Chemical Intermediates benefited from 3% higher selling prices and 2% higher volume/mix. Eastman lowered its 2025 capital expenditure target to approximately $550 million and expects to achieve cost reductions of around $75 million, net of inflation. Second-quarter 2025 adjusted EPS is projected to range between $1.7 and $1.9.

Analysts Adjust Ratings and Price Targets Following Q1 2025 Results

Morgan Stanley analyst Vincent Andrews maintained an Overweight rating but lowered the price target from $125 to $115.
JP Morgan analyst Jeffrey Zekaukas downgraded from Overweight to Neutral and the price target from $112 to $76.
KeyBanc analyst Aleksey Yefremov maintained a Neutral rating and reduced the price target from $120 to $106.

Which Analyst has the best track record to show on EMN?

Analyst Michael Sison (WELLS FARGO) currently has the highest performing score on EMN with 15/25 (60%) price target fulfillment ratio. His price targets carry an average of $8.52 (10.46%) potential upside. Eastman Chemical Company stock price reaches these price targets on average within 409 days.

AbbVie Reports Q1 Results and Raises Full-Year 2025 EPS Guidance

AbbVie reported first-quarter net revenues of $13.343 billion, surpassing analysts’ expectations of $12.93 billion, marking an 8.4% increase on a reported basis, or 9.8% on an operational basis. The immunology portfolio contributed $6.264 billion, reflecting a 16.6% increase on a reported basis and 18.1% on an operational basis.

Skyrizi generated $3.425 billion in net revenues, a 70.5% increase, while Rinvoq contributed $1.718 billion, up 57.2%. Humira’s contribution dropped to $1.121 billion, reflecting a 50.6% decrease. The neuroscience portfolio generated $2.282 billion, a 16.1% increase, driven by Vraylar ($765 million, +10.3%) and Botox Therapeutic ($866 million, +15.8%).

Oncology net revenues reached $1.633 billion, with Imbruvica contributing $738 million (-11.9%) and Venclexta showing $665 million (+8.3%). The aesthetics portfolio saw a decline of 11.7%, totaling $1.102 billion, primarily due to reduced sales in Botox Cosmetic and Juvederm. AbbVie reported first-quarter earnings per share (EPS) of $2.46, surpassing the analyst estimate of $2.39.

For full-year 2025, AbbVie has raised its adjusted diluted EPS guidance to a range of $12.09 to $12.29, up from the previous range of $11.99 to $12.19.

Analyst Increases Price Target and Maintains Rating

Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $241 to $250.
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating with a $215 price target.

Which Analyst has the best track record to show on ABBV?

Analyst Geoff Meacham (CITI) currently has the highest performing score on ABBV with 12/13 (92.31%) price target fulfillment ratio. His price targets carry an average of $24.86 (13.07%) potential upside. AbbVie stock price reaches these price targets on average within 285 days.